Clinical Policy: Naproxen Oral Suspension (Naprosyn)
Reference Number: HIM.PA.130
Effective Date: 12.01.17
Last Review Date: 11.18
Line of Business: HIM

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Naproxen oral suspension (Naprosyn®) is a non-steroidal anti-inflammatory drug.

FDA Approved Indication(s)
Naprosyn suspension is indicated:
- For the relief of the signs and symptoms of rheumatoid arthritis
- For the relief of the signs and symptoms of osteoarthritis
- For the relief of the signs and symptoms of ankylosing spondylitis
- For the relief of the signs and symptoms of juvenile idiopathic arthritis
- For the relief of the signs and symptoms of tendonitis
- For the relief of the signs and symptoms of bursitis
- For the relief of the signs and symptoms of acute gout
- For the management of pain
- For the management of primary dysmenorrhea

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Naprosyn oral suspension is medically necessary when the following criteria are met:

I. Initial Approval Criteria
A. Request for Naprosyn Oral Suspension (must meet all):
   1. Age ≥ 2 years;
   2. Documentation supports inability to use naproxen oral tablets;
   3. Dose does not exceed 1500 mg per day (60 mL per day).

   Approval duration: 12 months

B. Other diagnoses/indications:
   1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): HIM.PHAR.21 for health insurance marketplace.

II. Continued Therapy
A. Request for Naprosyn Oral Suspension (must meet all):
1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. If request is for a dose increase, new dose does not exceed 1500 mg per day (60 mL per day).

**Approval duration: 12 months**

**B. Other diagnoses/indications (must meet 1 or 2):**
1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.
   
   **Approval duration: Duration of request or 12 months (whichever is less); or**
2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): HIM.PHAR.21 for health insurance marketplace.

**III. Diagnoses/Indications for which coverage is NOT authorized:**
   
   **A.** Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – HIM.PHAR.21 for health insurance marketplace.

**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*
FDA: Food and Drug Administration

*Appendix B: Therapeutic Alternatives*
This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>naproxen oral tablets</td>
<td><strong>Ankylosing Spondylitis, Osteoarthritis, Rheumatoid Arthritis</strong>&lt;br&gt;250-500 mg PO BID&lt;br&gt;&lt;br&gt;<strong>Bursitis, Pain, Primary Dysmenorrhea, Acute Tendonitis</strong>&lt;br&gt;500 mg PO followed by 250 mg Q6-8 hrs&lt;br&gt;&lt;br&gt;<strong>Acute Gout</strong>&lt;br&gt;750 mg PO followed by 250 mg PO Q8 hrs until attack has subsided&lt;br&gt;&lt;br&gt;<strong>Juvenile Idiopathic Arthritis</strong>&lt;br&gt;10 mg/kg/day PO in two divided doses</td>
<td>1500 mg/day</td>
</tr>
</tbody>
</table>

*Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.*
Appendix C: Contraindications
Not applicable

V. Dosage and Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ankylosing spondylitis, Osteoarthritis, Rheumatoid arthritis</td>
<td>250-500 mg PO BID</td>
<td>1500 mg/day</td>
</tr>
<tr>
<td>Bursitis, Pain, Primary dysmenorrhea, Acute tendonitis</td>
<td>500 mg PO followed by 250 mg Q6-8 hrs</td>
<td>1250 mg/day</td>
</tr>
<tr>
<td>Acute gout</td>
<td>750 mg PO followed by 250 mg PO Q8 hrs until attack has subsided</td>
<td>1250 mg/day</td>
</tr>
<tr>
<td>Juvenile idiopathic arthritis</td>
<td>10 mg/kg/day PO in two divided doses</td>
<td>1500 mg/day</td>
</tr>
</tbody>
</table>

VI. Product Availability
Oral suspension: 125 mg/5 mL

VII. References

Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Reviews, Revisions, and Approvals</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy created</td>
<td>09.01.17</td>
<td>11.17</td>
</tr>
<tr>
<td>4Q 2018 annual review: no significant changes; references reviewed and updated.</td>
<td>07.16.18</td>
<td>11.18</td>
</tr>
</tbody>
</table>

Important Reminder
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health
CLINICAL POLICY
Naproxen Oral Suspension

plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

For Health Insurance Marketplace members, when applicable, this policy applies only when the prescribed agent is on your health plan approved formulary. Request for non-formulary drugs must be reviewed using the non-formulary policy; HIM.PA.103.

©2017 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise
published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.